Login | Users Online: 546  
Home Print this page Email this page Small font sizeDefault font sizeIncrease font size   
Home | About us | Editorial board | Search | Ahead of print | Current Issue | Archives | Submit article | Instructions | Subscribe | Advertise | Contact us
Year : 2000  |  Volume : 1  |  Issue : 7  |  Page : 258-263

Newer orally active antiplatelet agents: DO they have an edge over aspirin?

Dharma Vira Heart Centre, Sir Gangaram Hospital Rajinder nagar, New Delhi, India

Correspondence Address:
Abhay K Pande
B4/7 1, Azad Aparments, Sri Aurobindo Marg, Hauz Khas, New Delhi 110016
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

An extensive body of research conducted in the past 25 years has helped foster understanding of the mechanisms and pathogenesis of the acute coronary syndromes and occlusive disease. The role of platelet and the endothelium in the pathogenesis of atherosclerosis and subsequent ischemic events is well established. The field of antiplatelet therapy is rapidly expanding with the availability of newer antiplatelet agents. However, at the present time, there is no convincing data available that other antiplatelet drugs are superior to aspirin. Aspirin remains the cornerstone of therapy for various ischemic disorders and the foundation on which other therapies are added, both in the short and long term.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded43    
    Comments [Add]    

Recommend this journal